HC Wainwright将Alnylam制药公司升级为收购公司,设定了400美元的价格目标。 HC Wainwright upgrades Alnylam Pharmaceuticals to Buy, setting a $400 price target.

HC Wainwright将Alnylam制药公司(NASDAQ:ALNY)定为买家,规定价格目标为400美元。 HC Wainwright has rated Alnylam Pharmaceuticals (NASDAQ:ALNY) as a Buy, setting a price target of $400. 该公司报告,Q2收入为每股0.13美元,超过估计数(0.74美元),收入达6.5983亿美元,比上一年增加107%。 The company reported Q2 earnings of ($0.13) per share, surpassing estimates of ($0.74), with revenues reaching $659.83 million, up 107% year-over-year. 分析员一般将其评为中速购买,平均目标是278.59美元。 Analysts generally rate it as a Moderate Buy with an average target of $278.59. 值得注意的内幕交易包括CEO Yvonne Greenstreet和其他董事的重要股票销售。 Notable insider trading includes significant stock sales by CEO Yvonne Greenstreet and other directors.